ClinicalTrials.gg

Lymphoma, T-Cell, Peripheral clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 372 studies for Lymphoma, T-Cell, Peripheral across more than 10 countries. 110 are recruiting or about to start. 234 of them are mainly about Lymphoma, T-Cell, Peripheral (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
139
Recruiting
76
Status unknown
46
Terminated
46
Not yet recruiting
29
Active, not recruiting
17

Phase

Phase 2
193
Phase 1
150
Phase 3
27
Early Phase 1
9
Phase 4
5

Where

United States
164
China
114
Italy
35
France
29
Spain
25
Canada
20

Who develops what

Add Lymphoma, T-Cell, Peripheral to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 20 programs from 13 companies, 8 with this as their studies’ main aim; 2 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Beijing Biotech, Boryung Pharmaceutical and Chipscreen Biosciences here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
GemcitabineRecent, repeated
Evidence
  • NCT07234162 · Dizal Pharmaceuticals · Phase 3 · live · comparator · “Gemcitabine” · registered Nov 2025
  • NCT06522737 · SecuraBio · Phase 3 · live · comparator · “Gemcitabine” · registered Jul 2024
  • NCT01482962 · Takeda · Phase 3 · comparator · “Gemcitabine” · registered Nov 2011
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed22 studies
VincristineRecent, repeated
Evidence
  • NCT07676175 · BeBetter Med Inc · Phase 2 · live · background · “Vincristine Sulfate for Injection” · registered Jun 2026
  • NCT06947967 · Chipscreen Biosciences, Ltd. · Phase 3 · live · background · “CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)” · registered Apr 2025
Bristol-Myers Squibb9% of its industry studies22 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT07676175 · BeBetter Med Inc · Phase 2 · live · background · “Cyclophosphamide for Injection” · registered Jun 2026
  • NCT05883449 · Affimed GmbH · Phase 2 · background · “Cyclophosphamide” · registered May 2023
  • NCT04569032 · Pfizer · Phase 2 · background · “cyclophosphamide” · registered Sep 2020
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed22 studies

9 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
golidocitinib☆ Track1 live phase-3 study: NCT07234162Dizal Pharmaceuticals
tucidinostat☆ Track1 live phase-3 study: NCT06947967Chipscreen Biosciences, Ltd.

The 2 in phase 3 with the nearest primary completion, of 20 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jan 2027 est.XNW5004 · Evopoint Biosciences Inc. · Phase 2 main aimNCT06702605 To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma — primary endpoint: Objective response rate (ORR) assessed by independent review committee (IRC) · 50 enrolled
  • 14 Mar 2027 est.Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module, Autologous BCMA/CD38 dual-target CAR-T module, Autologous BCMA/GPRC5D dual-target CAR-T, Autologous CD33/CD123 dual-target CAR-T module, Autologous CD33/CLL1 dual-target CAR-T module, Autologous CD5/CD7 dual-target CAR-T module · Beijing Biotech · Phase 2 named, not the main aimNCT07523555 Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies — primary endpoint: Incidence of dose-limiting toxicities (DLTs) by module and dose level · 96 enrolled
  • Sep 2027 est.bosmolisib · Boryung Pharmaceutical Co., Ltd · Phase 2 main aimNCT07180771 A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. — primary endpoint: Confirmed Objective Response Rate (ORR) (CR + PR) assessed by a blinded independent reviewer at the central lab according to the 2014 Lugano criteria · 44 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Lymphoma, T-Cell, Peripheral studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 20 open · JAK inhibitors 18 open · HDAC inhibitors 13 open · Immune checkpoint inhibitors 11 open · Antimetabolites 9 open

Coming up

31studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger. 5 (7%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 76
AgeWomenMen
102 (3%)2 (3%)
1873 (96%)73 (96%)
3075 (99%)75 (99%)
4073 (96%)73 (96%)
5073 (96%)73 (96%)
6573 (96%)73 (96%)
7556 (74%)56 (74%)
8534 (45%)34 (45%)

Across all 372 studies, recruiting or not: 31% stop at 75 or younger and 8% at 65; 13% take children; 0% are for women only and 0% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lymphoma, T-Cell, Peripheral studies take

Of 64 phase 2 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 61 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 149 mo33–61 · 42 studies——
Phase 1/249 mo39–65 · 31 studies——
Phase 261 mo38–96 · 64 studies—65 mo47–110 · 44 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 372. Browse all 372 → or search them.